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Introduction: More than 50% of HIV-positive patients experience neuropsy-
chiatric adverse reactions following efavirenz therapy. Discontinuation of efa-
virenz due to its neuropsychiatric side effects has been reported in 2 -- 13% of
patients. Dizziness, headache, nightmares, abnormal dreams, mild cognitive
difficulty, sleep disturbance (somnolence and insomnia), impaired concentra-
tion, depression, hallucination, delusion, paranoia, anxiety, agitation, aggres-
sive behavior, mania, emotional labiality, catatonia, melancholia, psychosis,
and fatigue are the most reported efavirenz adverse reactions.
Areas covered: In this review, potential benefits of cyproheptadine in preven-
tion and management of HIV/antiretroviral-associated neuropsychiatric com-
plications are evaluated. The available evidence was collected by searching
Scopus, PubMed, Medline, Cochrane central register of controlled trials, and
Cochrane database systematic reviews.
Expert opinion: Cyproheptadine is a cheap and safe drug that does not have
significant interactions with antiretroviral drugs. Cyproheptadine’s common
side effects including increasing appetite and weight gain can be useful in
HIV-positive individuals with their decreased appetite and weight loss. There
is limited evidence regarding the effectiveness of cyproheptadine in neuro-
psychiatric disorders. It is essential to evaluate cyproheptadine efficacy in
the prevention and management of neuropsychiatric complications of HIV/
antiretroviral infection in well-designed studies in the future.
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1. Introduction
Although antiretroviral therapy (ART) can suppress human immune deficiency
virus (HIV) replication and decrease morbidity and mortality in HIV-positive
individuals, they have numerous adverse drug reactions (ADR). Based on the seve-
rity of the ADR, modification or cession of treatment may be required [1]. Efavirenz
is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) with favorable
pharmacokinetic characteristics and few known ADR. These properties make it as
a first-line drug in combination with other ART for treatment of HIV infection [2,3].
More than 50% of patients who take efavirenz will experience neuropsychiatric
ADR of this drug [4,5]. Discontinuation of efavirenz due to its neuropsychiatric
ADR has been reported in 2 -- 13% of patients [6-9]. Interruption of efavirenz can
promote viral resistance to this drug and other NNRTIs [9]. Efavirenz ADRs usually
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are mild to moderate and they generally include dizziness,
headache, nightmares, abnormal dreams, mild cognitive diffi-
culty, sleep disturbance (somnolence, insomnia), impaired
concentration, and fatigue [10]. Depression following efavirenz
therapy was reported in 2% of patients [11]. Severe neuropsy-
chiatric ADR such as severe depression with suicidal attempt
(1 per 1,000), hallucination, delusion, paranoia, anxiety,
agitation, aggressive behavior, mania, emotional labiality,
catatonia, melancholia, and psychosis were detected in less
than 2% of patients [5,6,10,12,13]. There are some case reports
of recurrence of posttraumatic stress disorders after starting
efavirenz-based ART [14]. Typically, these ADR begin after
first doses and relive within 1 month of efavirenz therapy [8,15].
In 13% of patients, these ADR persisted for 1 year
period [7,16]. Severe psychiatric disorders are more likely in
patients with underlying mental illnesses or history of drug
abuse [4]. Female sex can be a risk factor for efavirenz-induced
central nervous system toxicity [8]. The mechanism of these
ADR is not well described [17]. Some mechanisms were pro-
posed in the different studies [10,13,17]. Efavirenz may inhibit
creatine kinase (CK), an enzyme responsible for cellular
energy production in tissues with high energy consumption
such as brain. Decreased CK activity can cause brain ischemia
and neuronal loss [18]. CYP2B6 polymorphism can play essen-
tial role in slowing clearance of efavirenz and following high
plasma level of this drug [19]. Efavirenz is administrated with
dose of 600 mg per day regardless of the body weight in the
adult patient. In patient with low body weight, it causes a
higher concentration of efavirenz in blood and CNS and
may lead to CNS toxicity [10]. The protein binding of efavir-
enz is very high, and in patient with hypoalbuminemia,
unbound fraction of efavirenz is increased in plasma, and
efavirenz diffusion to CNS becomes more readily that can
cause ADR [10]. In addition, high-fat meals can increase
plasma level of efavirenz and CNS toxicity [20]. The severity
of these ADR often is dose-dependent and ameliorated with
dose reduction [10,13]. Increasing the efavirenz doses slowly
over 2 weeks, reduced incidence and intensity of its neuropsy-
chiatric ADR while maintaining its efficacy [5]. The safety of
dose escalation has not been established, and the efavirenz
manufacturer does not recommend this approach due to risk
of drug resistance [2]. Nevirapine is another drug in NNRTI
class. There are some reports of psychiatric ADR such as vivid
dream with this drug [21]. Zidovudine, lamivudine, and
didanosine also may cause psychiatric complications. Abacavir
can induce psychosis and mania when used in combination
with other ART [22]. Neuropsychiatric ADR of ART and
neuropsychiatric complications of HIV infection may overlap
significantly, and it may be difficult to differentiate them
from each other. Psychiatric complications of HIV infection
varies from depression to mania and psychosis [1]. The neuro-
psychiatric complications of HIV may be related to immune
system activation and viral infection of the brain macrophages
and microglia [22].
1.1 Management of ART-associated neuropsychiatric
complications
ART-associated neuropsychiatric complications should be
managed with regard to the severity. Mild complications
usually are well tolerated and self-limited [22,23]. If these
ADR do not resolve spontaneously within 2 weeks of therapy,
psychotropic medication can be useful [6]. In patients with
severe reactions, modification or discontinuation of offending
drug may be necessary [22,23]. Several psychotropic categories
including antidepressants (citalopram, sertraline, mirtazepine,
reboxetine, venlafaxine), antipsychotics (olanzapine, risperi-
done, amisulpride, sulpiride), mood stabilizers (valproate,
lamotrigine), and anxiolytics (oxazepam, lorazepam, temaze-
pam, zopiclone) are proposed for relieving neuropsychiatric
ADR of efavirenz [24]. The interaction between psychotropic
drugs and antiretroviral medications is a considerable pro-
blem [15,22]. Selection of an appropriate psychotropic agent
with a broad spectrum activity and minimum drug interac-
tion with ART is a challenging point in prevention or
treatment of ART-associated neuropsychiatric ADR.
Cyproheptadine is an available, cheap, and relatively safe
5-hydroxytryptamine 2 (5-HT2) receptors antagonist. Also
its affinity to interact with dopamine, histamine, adrenergic,
and muscarinic receptors is relatively high [25]. Cyprohepta-
dine is extensively metabolized in the liver and principally
excreted as inactive metabolites in the urine and feces. The
principal metabolite found in human urine has been identi-
fied as a quaternary ammonium glucuronide conjugate of
cyproheptadine. Cyproheptadine may have additive effects
with alcohol and other CNS depressant such as hypnotics,
sedative, tranquilizers, and antianxiety agents. Monoamino
oxidase inhibitors can prolong and intensify anticholinergic
Article highlights.
. Antiretroviral medications and HIV infection cause some
neuropsychiatric complications such as dizziness,
headache, nightmares, abnormal dreams, mild cognitive
difficulty, sleep disturbances, depression, hallucination,
delusion, paranoia, anxiety, agitation, aggressive
behavior, mania, and psychosis.
. Cyproheptadine is an available, cheap, and relatively
safe 5-hydroxytryptamine 2 (5-HT2) receptors antagonist.
. Cyproheptadine showed beneficial effects in the
treatment of nightmare, sleep disorders, acute and
chronic schizophrenia, anxiety, depression, recurrent
and posttraumatic nightmares, and in the prevention of
vascular types of headache especially migraine attacks in
non--HIV-positive individuals.
. It seems that cyproheptadine can be useful in the
treatment of neuropsychiatric disorders that are related
to ART and/or HIV infection.
. Common side effects of cyproheptadine are increase
in appetite and weight gain which can be useful in
HIV-positive patients.
This box summarizes key points contained in the article.
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effects of cyproheptadine. It does not have significant drug
interaction through cytochrome P450 isoenzymes [26-28].
Some neuropsychiatric effects of cyproheptadine are same
as clozapine [25]. Also, cyproheptadine and clozapine have
the similar mechanism in food intake-enhancing effect in an
experimental study [29]. Cyproheptadine has beneficial effects
in the treatment of acute and chronic schizophrenia, anxiety,
and depression [30-34]. It also may be effective in treatment of
recurrent and posttraumatic nightmares and in the prevention
of vascular-type headaches, especially migraine attacks [35-39].
Cyproheptadine is a hypnotic drug that can induce sleep and
also improves its quantity and quality [40]. Common side
effects of cyproheptadine are appetite improvement and
weight gain [41]. It seems that cyproheptadine can be useful
in the treatment of neuropsychiatric disorders that are related
to HIV/ART and improve HIV-positive patients’ appetite
and weight gain. In this review, potential benefits of cypro-
heptadine in prevention and treatment of ART-associated
neuropsychiatric problems will be evaluated based on the
available evidences.
2. Methods
The available evidences were collected by searching Scopus,
PubMed, Medline, Cochrane central register of controlled
trials, and Cochrane database systematic reviews. Cyprohepta-
dine, depression, psychosis, hallucination, delusion, headache,
nightmare, anxiety, sleep, insomnia, appetite, weight, HIV,
HAART, and ART were used as keywords to search. We
selected the evidences that supported the possible benefits of
cyproheptadine in HIV/ART complications. No time limit
was applied for selecting articles.
The numbers of retrieved articles were 75. The irrelevant
articles (animal and basic experimental studies, in vitro
studies, non-English language reports) have been excluded.
Finally, we have included 27 relevant human studies up-to-
date of publication. The important studies are organized
in Table 1.
3. Cyproheptadine and neuropsychiatric
adverse reactions
3.1 Cyproheptadine and insomnia/nightmare
Cyproheptadine seems to be effective in treatment of recur-
rent and posttraumatic nightmares. Two cases of recurrent
nightmares that were treated with 4 -- 8 mg cyproheptadine
at bedtime have been reported. These patients did not experi-
ence nightmares following cyproheptadine addition, but the
dreams recurred after discontinuation of cyproheptadine.
One of the patients continued cyproheptadine electively
during his stress periods. The second case discontinued cypro-
heptadine after 1 week due to his daytime sedation [35].
In a retrospective review, the efficacy of cyproheptadine
(4 -- 12 mg at bedtime) was evaluated in treatment of night-
mares associated with posttraumatic stress disorders in nine
patients. Full remission or reduction in the intensity and
recurrence of nightmares was detected following cyprohep-
tadine therapy in these patients. In this study, the cyprohep-
tadine effects initiated after few days of treatment and its
optimum effects were observed within 3 -- 4 weeks. Cypro-
heptadine also improved the patients’ sleep quality. In two
patients, the nightmares relapsed after cyproheptadine discon-
tinuation and disappeared after restarting cyproheptadine.
Most of the patients reported improvement in their night-
mares in follow-up periods at Month 9 or later. It was
suggested that anticholinergic and antiserotonergic properties
of cyproheptadine are responsible for reduction of rapid eye
movement (REM) sleep and also reduction or remission of
nightmares [42]. Rijnders et al. reported a case of posttraumatic
nightmares (up to five nights a week) following her rape. Up
to 12 mg cyproheptadine was prescribed for the patient and
her severity and frequency of nightmares diminished to one
per week. They used electroencephalogram (EEG), poly-
somnography data, and serum levels of cyproheptadine
for evaluation of the patient’s clinical status. Nearly normal
sleep’s pattern was reported in the polysomnography
following cyproheptadine administration. Serum level of
cyproheptadine was 6 µg/L after administration of 12 mg of
cyproheptadine in this patient [37].
Tokunaga et al. have evaluated the effects of some H1-
receptot antagonists including oral cyproheptadine (at doses of
5 and 10 mg/kg) on the sleep--wake cycle in sleep-disturbed
rats in comparison with oral nitrazepam (at doses of 0.5 and
1.0mg/kg) in an experimental study. The EEG and electromyo-
gram (EMG) were recorded by implanting electrodes into the
frontal cortex and the dorsal neck muscle of rats, respectively.
They used an electroencephalograph for recording EEG and
EMG and Sleep Sign ver. 2.0 for analyzing EEG and EMG.
EEG and EMG were recorded for 6 h after oral administration
of drugs. In this study, cyproheptadine decreased the total
waking time. It also increased the total non-REM sleep time,
slow wave sleep, and delta activity [40].
Although most available evidences regarding beneficial
effects of cyproheptadine in treatment of nightmare and sleep
quality are based on the case reports or series, but due to the
comprehensive clinical, EEG, EMG, and polysomnography
evaluations in these reports, it can be concluded that cyprohep-
tadine is an attractive agent for relieving nightmares and
improvement of sleep quality and quantity in HIV/ART cases.
3.2 Cyproheptadine effects on anxiety, depression,
and schizophrenia
It has been reported that 5-HT2 receptor antagonists (such as
cyproheptadine, ritanserin, and mianserin) have potential
beneficial effects in ameliorating of schizophrenia, anxiety,
and depression symptoms [30,31].
3.2.1 Cyproheptadine and anxiety
Cyproheptadine with its sedative effects can be a suitable
agent in ameliorating of the anxiety symptoms in different
Potential benefits of cyproheptadine in HIV positive patients under treatment with antiretroviral drugs
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populations. Results of a double-blind comparative trial of
mianserin and diazepam in 67 patients with anxiety disorders
have been reported. Patients randomly received mianserin
(10 mg three times a day) or diazepam (5 mg three times a
day) orally for 4 weeks in a double-blind condition followed
by crossing-over all patients to placebo for further 3 weeks
in a single-blind condition. Hamilton Anxiety Rating Scale
(HARS), Physician’s Global Rating, Patient’s Global Assess-
ment, and Treatment Emergent Symptoms Scale were com-
pleted at base line and at weekly intervals. Patients in both
the groups had similar improvement in different scores during
first 4 weeks of treatment. No significant change was observed
in the scores in both groups during subsequent 3 weeks of
placebo therapy. In this study mianserin showed anxiolytic
and side effects similar to diazepam [43].
The efficacy of a selective 5-HT2 antagonist, that is, ritan-
serin was investigated in 48 patients with generalized anxiety
disorder for 4 weeks in a double-blind trial. Ritanserin 5 mg
twice daily was administered for 22 patients, and 26 patients
were included in the placebo group. The HARS and the
Visual Analog Mood Rating Scale were used for assessing
symptoms. The ritanserin-treated patients had significant
improvement in HARS scores, especially in the insomnia
items, tension, and depressed mood, and they became more
energetic and relaxed according to the Mood Rating Scale.
The statistically significant differences between two groups
were detected after 2 weeks [44].
Although a few studies have evaluated the antianxiety effects
of 5-HT2 antagonists, but as these studies were well designed
and double blinded with control groups, it can be concluded
that these agents may be considered for symptomatic treatment
of anxiety disorders in different populations.
3.2.2 Cyproheptadine and depression
There are limited studies that have evaluated the role of cypro-
heptadine monotherapy or as adjunct therapy with other
antidepressants in management of depression. Murphy et al.
also reported that mianserin is effective as imipramine in the
management of depression in a double-blind, comparative
multicenter trial. Mianserin 20 mg three times daily or imipr-
amines 50 mg three times daily for 4 weeks were randomly
administered to 109 male and female depressive individuals.
Severity of depression was assessed by a 17-items physician
rating scale and a 10-items visual analogue self-rating scale
before treatment and on days 7, 14, and 28 of treatment.
No significant differences in antidepressant effects were seen
between two groups [43]. Greenway et al. also reported anti-
depressant effects of cyproheptadine in six patients with major
depression in a double-blind, crossover trial. Cyproheptadine
or placebo was randomly prescribed as 4 mg, four times per
day for 4 weeks, then 8 mg four times per day for another
4 weeks, and then crossed-over the patients to cyproheptadine
or placebo. Hamilton Depression Rating Scale and 1-mg
dexamethasone suppression test were applied immediately
before stating cyproheptadine and at 4 weeks intervals
during this study period. Two patients with non-suppressible
dexamethasone suppression tests could not tolerate cypro-
heptadine due to their anxiety and irritability. Hamilton
Depression Rating Scale scores decreased significantly in
four patients with suppressible dexamethasone suppression
tests during the study [45].
Based on the results of these few studies with small sample
size, the judgment about positive effects of cyproheptadine as
monotherapy or adjunct therapy in treatment of depression is
difficult. Well-designed, randomized clinical trials are needed
to confirm the role of cyproheptadine in the treatment
of depression.
3.2.3 Cyproheptadine and schizophrenia
Several studies have evaluated the potential benefits of cypro-
heptadine as augmentation therapy with a typical antipsy-
chotic (such as haloperidol) in the management of negative
and positive symptoms of schizophrenia. Silver et al. evaluated
the effects of cyproheptadine in 10 patients with chronic
schizophrenia. Prior to cyproheptadine administration,
patients were stabilized on lowest effective dose of haloperidol
for 4 weeks. Cyproheptadine was started with a dose of 4 mg
per day and was titrated up to 32 mg per day over 2 weeks.
This dose was continued for another 4 weeks and then was
tapered down within 1 week. Clinical response was assessed
at baseline and at weekly intervals during the study period
and after 2 weeks of cyproheptadine withdrawal. The Brief
Psychiatric Rating Scale (BPRS), the Clinical Global Inven-
tory (CGI), and the Krawiecka-Goldberg Scale (KGS) were
used for the patients’ overall clinical state assessment. In addi-
tion, Simpson Angus (SA) scale and Negative Symptom
Rating Scale (NSRS) were, respectively, applied for the
patients’ extra-pyramidal (EPS) and negative symptoms evalu-
ation in this study. The clinical response to cyproheptadine in
four patients was categorized as moderate to good (20 -- 43%
improvement in the total BFRS scores). The most significant
effect of cyproheptadine was reported in the improvement of
negative symptoms of the patients. The authors concluded
that cyproheptadine can ameliorate both positive and negative
symptoms in chronic schizophrenic patients, and the most
significant improvement was seen in negative symptoms [46].
Effects of cyproheptadine in the treatment of chronic
schizophrenia were evaluated in a randomized, double-blind
study. Haloperidol 10 -- 60 mg daily was prescribed for
20 patients for at least 4 weeks prior to the trial. Patients
received placebo or oral cyproheptadine 4 mg daily and then
titrated up to 32 mg over 2 weeks. Patients were undertreated
with this dose for 4 weeks. BPRS and NSRS were used for
assessment of patients’ negative symptoms and SA scale for
extrapyramidal side effects in this study. The scales were com-
pleted at baseline, 4 and 6 weeks after treatment. All scales
except SA showed no significant differences between two
groups during the study. The results of this study showed
that cyproheptadine did not have any effects on the negative
symptoms of schizophrenia, but it caused fewer EPS in
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comparison with placebo [47]. Lee et al. investigated the anti-
schizophrenic effects of cyproheptadine in 46 chronic schizo-
phrenic patients in a randomized, double-blind clinical trial.
Patients received up to 12 mg haloperidol for 2 weeks, and
then received placebo or oral cyproheptadine (8 mg daily for
first 3 days and then tapered up to 24 mg daily on Day 7)
for 6 weeks. BPRS, CGI, and SA were, respectively, used for
the assessment of negative, positive, and EPS symptoms of
the patients at baseline and biweekly until end of the study.
They did not find any significant differences between two
groups for any scales during the study period except SA.
They concluded that concomitant administration of cypro-
heptadine and haloperidol did not have any further beneficial
effects over haloperidol in chronic schizophrenia except fewer
extrapyramidal side effects [33]. In another study, cyproheptadine
with dose of 20mg as a single dose was prescribed for 18 patients
with chronic schizophrenia in a double-blind placebo-controlled
crossover study. Cyproheptadine did not have any effect on
neuropsychological tests such as stroop, verbal fluency,
Wisconsin card sort, trail making, and memory. They con-
cluded that single dose of cyproheptadine did not have
pronounced effect on the frontal lobe function [48].
Akhondzadeh et al. reported the results of a randomized,
double-blind, placebo-controlled study of cyproheptadine in
30 patients with chronic schizophrenia. Patients were
randomly treated with 30 mg haloperidol and 24 mg cypro-
heptadine per day or 30 mg haloperidol daily plus placebo
for 8 weeks. Positive and negative syndrome scale (PANSS)
was used to measure patients’ outcome at baseline and after
2, 4, 6, and 8 weeks after initiation of the treatment. PANSS
scores were higher in placebo group in comparison with
cyproheptadine group at weeks 4, 6, and 8. A significant
difference in PANSS scores was detected from Week
6 between two groups. They concluded that cyproheptadine
may be useful in ameliorating of negative symptoms of schizo-
phrenia [34]. In another study, Chaudhry et al. evaluated
effects of cyproheptadine on the frontal lobe function and
also the negative symptoms in 18 patients with schizophrenia
that were stabilized on a depot neuroleptics in a randomized,
double-blind, crossover study. Oral cyproheptadine 8 mg
twice per day or placebo was administered for 4 weeks and
subsequently after 6 -- 8 weeks washout period, patients in
each group were crossed-over. They used neuropsychological
tests (verbal fluency, stroop color word task, and trial making)
and rating scales (Manchester scale, SA, and PANSS) for
assessment of patients on days 7 and 28. They reported that
there were not any differences between placebo or treatment
group in all psychopathological rating scales during the
study period, but significant improvement was reported in
neurological tests in patients in the treatment group. They
suggested that 5-HT2 antagonists such as cyproheptadine
can modulate the frontal lobe function, but they did not
change negative symptoms of schizophrenia [49].
Although available evidences support the beneficial effects
of cyproheptadine as adjunct therapy in management of
negative symptoms of schizophrenia and ameliorating of
EPS effects of typical antipsychotics, its beneficial effects on
positive symptoms is questionable. Different doses of cypro-
heptadine were used in the available studies. Also, small
sample size and application of different neuropsychiatric
scales for evaluation of cyproheptadine effects are other limi-
tations of these studies. It must be emphasized that all
available evidences about positive effects of cyproheptadine
in schizophrenic patients are based on adjunct therapy with
an effective antipsychotic. More studies with sufficient sample
size are required to clarify the role of cyproheptadine in
treatment of schizophrenia in HIV/AIDS patients.
3.3 Cyproheptadine and headache
Cyproheptadine with dose of 4 -- 12 mg per day is commonly
used as migraine headache prophylaxis [36,37]. Analgesic and
antidepressant properties of ritanserin (a 5-HT2 antagonist
such as cyproheptadine) were evaluated in 38 patients with
depression and chronic headache in a double-blind trial.
This study was divided in to three periods; 1 month run in
period, 3 months treatment period, and 1 month washout
period. The patients randomly received oral ritanserin,
10 mg daily or amitriptyline, and 50 mg daily during the
treatment period. Patients recorded their headache episodes,
duration, severity, and analgesics requirement. The investiga-
tors also calculated pain total index (PTI) and completed
Hamilton Depression Rating Scale and Hamilton anxiety
Rating Scale in monthly interval until end of the washout
period. Ritanserin reduced Hamilton Depression Rating Scale
and Hamilton Anxiety Rating Scale scores significantly during
both the treatment and washout periods. Reduction in PTI
and analgesic consumption were similar between ritanserin-
and amitriptyline-treated groups. Results of the study showed
that the anti-headache activity and antidepressive properties of
ritanserin is similar to amitriptyline [50]. Rao et al. evaluated
role of propranolol and cyproheptadine in the migraine pro-
phylaxis in a controlled double-blind trial. They compared
the efficacy of propranolol, cyproheptadine, combination of
them, and placebo in 259 patients with migraine headache.
The patients were classified into four groups: placebo, 2 mg
cyproheptadine twice a day, 40 mg propranolol twice a day,
and a combination of 2 mg cyproheptadine and 40 mg pro-
pranolol twice a day for 3 months. Amelioration in frequency,
duration, and severity of the patients’ headache were recorded
as 100 (complete relief), 75, 50, 25, and 0% (no relief) during
the study period. In this study cyproheptadine significantly
decreased the frequency, duration, and severity of the patients’
migraine attacks. The most statistically significant relief in the
patients’ headache attacks was detected in the combination
treatment of propranolol and cyproheptadine [51].
There are enough evidences to support the role of cypro-
heptadine in prevention of migraine-type headaches in
different populations, and it can be an effective alternative
for prevention of migraine-type headache in HIV/AIDS
patients.
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3.4 Cyproheptadine and appetite/weight gain
Cyproheptadine can stimulate appetite and cause moderate
weight gain. Cyproheptadine as an appetite stimulant has
been tried in patients with HIV infection with doses from
4 mg oral twice daily to four times daily [52]. Stiel et al.
described the mechanisms of cyproheptadine induced weight
gain through its effects on food intake and metabolism. Their
study had two parts. In part A of the study, effects of cypro-
heptadine in 12 healthy adults on ad libitum diets were
evaluated for 6 weeks in a double-blind method. Placebo
was administered for all subjects during first, second, fifth,
and sixth weeks. During the third and fourth weeks, placebo
or cyproheptadine was randomly administered for the sub-
jects. Due to drowsiness of cyproheptadine, placebo and
cyproheptadine were administered in one-half tablet (2 mg)
three times daily for the first 4 days and one tablet (4 mg)
three times per day for other days. Subjects’ weight, appetite,
and side effects were recorded daily. In addition, urine
samples were collected daily. All six subjects who received
cyproheptadine, experienced weight gain with a mean of
2.2 kg (1.4 to 3.1 kg) during the third and fourth weeks.
A mean of 0.45 kg weight gain during the first and second
weeks and a mean of 0.64 kg weight loss during fifth and sixth
weeks were detected in these subjects. Weight gain in the
treatment period (weeks 3 and 4) was significantly higher
than the first placebo period (weeks 1 and 2). Placebo subjects
gained only 0.14, 0.18, and 0.36 kg weight during each
2 weeks of the study, respectively, and their weight gain was
not statistically significant. Increase in appetite and food
intake was reported by majority of the subjects during cypro-
heptadine therapy periods. Urinary nitrogen, potassium, or
volume did not change significantly during each 2 weeks
study period. Drowsiness was reported by three subjects in
cyproheptadine group that decreased the patients’ normal
activity. In part B of the study, three patients in cyprohep-
tadine group were randomly selected and maintained on a
constant diet for another 3 weeks. They received placebo
one tablet three times per day during the first and third weeks
and cyproheptadine 4 mg three times daily during second
week of the study. Fasting blood glucose, plasma insulin,
plasma growth hormone (GH), and basal metabolic rates
were measured on days 1, 5, 8, 12, 15, 19, and 21 of the
study. In addition, the patients’ weight, appetite, and side
effects were recorded at those days. All patients experienced
weight gain with a mean of 0.73 kg under constant diet,
and their weight gain was statistically significant but was
less than that of subjects who were under ad libitum diet.
Fasting blood glucose, plasma insulin, GH, and basal meta-
bolic rate did not change during cyproheptadine therapy.
The investigators concluded that cyproheptadine can cause
weight gain in both adult and children by two possible
mechanisms. The major mechanism is an increase in appetite
and subsequently food intake. Other mechanism that plays
minor role is decrease in patient’s activity because of its
sedative effects [53].
Comer et al. reported the results of a residential study in
seven healthy volunteers that received oral cyproheptadine or
placebo for 18 days. Three types of diet were assessed in this
study: regular, low carbohydrate, and high carbohydrate
diet. Patients received placebo on days 1, 2, 3, and 6, and
cyproheptadine with dose of 4 mg on days 4 and 5 of each
diet. Total caloric intake was increased about 20% following
cyproheptadine consumption only in the volunteers that
were under the regular diet condition. Cyproheptadine caused
improvement in caloric intake by increasing the numbers of
eating occasions but not the eating occasion size [54].
In another study, Daviss et al. evaluated the benefits of
cyproheptadine in a retrospective chart review of 28 young
individuals with attention deficit hyperactivity disorder
(ADHD) who were under treatment with stimulants. Cypro-
heptadine ordered for them due to weight loss or insomnia.
Data from 21 patients who received cyproheptadine
(4 -- 8 mg every night) at least for 14 days were analyzed.
The patients’ weight changes were recorded during two time
spans. First time span was between initiation of stimulant
and the time when cyproheptadine was added (time 1). Sec-
ond time span was between initiation of cyproheptadine and
the last visit of the patients (time 2). In addition to sleep chart,
Clinician’s Global Impressions Improvement (CGI) scale was
used for evaluation of the patient’s insomnia during the two
time spans. Weight loss was detected in most patients on
stimulant alone. Weight gain was reported when cyprohepta-
dine was added to stimulant. Weight gain was significantly
faster in the second time span compared with the first time
span. At first, 17 patients had sleep problems when they
were under treatment with stimulant, and 11 out of them
experienced significant improvement in their sleep after
cyproheptadine was added to stimulant. The authors con-
cluded that cyproheptadine had beneficial effects in ADHD
patients who suffered from stimulants induced weight
loss [41].
Homnick et al. evaluated short-term effects of cyprohepta-
dine on appetite in 18 patients with cystic fibrosis (CF) in a
randomized, double-blind clinical trial. Patients received
placebo or cyproheptadine with dose of 2 mg four times daily
for 1 week and then increased to 4 mg four times daily for
11 weeks. Shwachman score, anthropometrics (weight,
height, body mass index, skin folds, and body composition
by bioelectric impedance analysis), spirometry, calorie intake,
days of oral (PO) and intravenous (IV) antibiotics, and
patients’ satisfaction were measured at baseline and every
4 weeks. Weight, height, BMI percentiles, ideal body
weight/height, weight for age z-scores, and fat and fat-free
mass were significantly increased in cyproheptadine group.
No significant changes were detected in spirometry and dura-
tion of IV or PO antibiotic treatment. The only side effect
was transient mild sedation. The authors concluded that
cyproheptadine can be used as appetite stimulant in CF
patients [55]. Homnick et al. also evaluated long-term effects
of cyproheptadine in the previous study. The patients received
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placebo or cyproheptadine, 4 mg four times daily for 9 months
in a randomized, double-blind manner. Anthropometrics,
spirometry, and duration of PO and IV antibiotics were
measured at baseline (end of the pervious study), 3, 6, and
9 months during the recent study. Patients who changed their
medication from placebo to cyproheptadine showed signifi-
cant weight gain over 3 -- 6 months, and those who continued
their cyproheptadine from the previous study maintained
weight gain during this period. No significant changes were
detected in spirometry and IV or PO antibiotic treatment.
They concluded that the cyproheptadine effect as appetite
stimulant maintained over the time in CF patients [56].
Epifanio et al. investigated short-term effects of cyprohep-
tadine on weight gain in 28 patients with CF in a randomized,
double-blind, placebo-controlled trial for 12 weeks. Patients
received placebo or cyproheptadine 4 mg three times daily.
Weight, height, and spirometry were measured at baseline
and at the end of 12 weeks trial. Body mass index and weight
were significantly increased in cyproheptadine group. They
found that cyproheptadine can be effective for inducing
weight gain during short time period [57].
In non-CF population, Rerksuppaphol et al. reported
results of a randomized, double-blind, placebo-controlled trial
in 70 malnourished children. Children received placebo or
cyproheptadine (0.1 mg/kg/dose) three times daily for
8 weeks. Anthropometrics parameters (weight, height, skin-
fold thickness, waist and hip circumferences, and fat compo-
sition by bioelectric impedance analysis) were measured at
baseline and every 2 weeks during the study period. Cypro-
heptadine group showed significantly higher absolute weight
gain than placebo at the end of the trial. They concluded
that cyproheptadine can be effective in gaining weight in a
short-term period [58].
In the available studies, different doses of cyproheptadine
have been evaluated in different populations as appetite stimu-
lant and promoter of weight gain. In addition, various assess-
ment tools were applied for evaluation of the cyproheptadine
effects on weight gain and appetite stimulation. Despite these
limitations, cyproheptadines traditionally used as an appetite
stimulant and besides its other beneficial effects, available evi-
dences support cyproheptadine use in HIV-positive individuals
that usually suffer from decreased appetite and weight loss.
3.5 Cyproheptadine and interactions with ART
The psychotropic medications that have been used for manage-
ment of HIV/ART-associated neuropsychiatric compli-
cations include antidepressants (such as citalopram, sertraline,
mirtazepine, reboxetine, venlaflaxine), antipsychotics (such as
olanzapine, risperidone), mood stabilizers (such as valproate,
lamotrigine), and anxiolytics (such as oxazepam, lorazepam,
temazepam). The psychotropic drugs can interact with antire-
troviral medications through cytochrome P450 pathways.
These interactions can change the blood levels of both groups
of drugs and may lead to toxicity [15,22]. Cyproheptadine does
not have significant interactions with antiretroviral medications
through cytochrome P450 [26-28]. It is a great benefit of cypro-
heptadine over psychotropic medications. With this favorable
pharmacokinetic profile, cyproheptadine can be a safe option
for treatment of some neuropsychiatric complications in
HIV/AIDS patients.
4. Expert opinion
In this review, different beneficial effects of cyproheptadine
for treatment of neuropsychiatric complications associated
with HIV/ART have been evaluated. Antiretroviral medica-
tions and HIV infection have some neuropsychiatric adverse
effects that may be improved with cyproheptadine. Different
studies have reported the efficacy of cyproheptadine and other
5-HT2 antagonists in the treatment of anxiety, depression,
negative and positive symptoms of schizophrenia, nightmares,
headache, and insomnia. These problems are the most com-
mon neuropsychiatric adverse effects that are associated with
HIV/ART. Although cyproheptadine have not evaluated in
the HIV-positive patients for these neuropsychiatric compli-
cations, based on the evidences from other populations, it
seems that cyproheptadine has the potential to ameliorate
HIV/ART-associated neuropsychiatric complications. Cypro-
heptadine also is an available, cheap, and relatively safe
medication. It does not have significant interactions with
antiretroviral drugs through cytochrome P450 pathways.
Cyproheptadine-related common side effects including
increasing appetite and weight gain can be useful in HIV-
positive individuals with decreased appetite and weight loss.
There are limited evidences about the efficacy of cypro-
heptadine in neuropsychiatric disorders. It is essential that
the efficacy of cyproheptadine in the management of neuro-
psychiatric side effects associated with HIV/ART be evaluated
in well-designed studies in the future.
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